Clinical trials: Renal Anemia
Malnutitrion, Chronic Kidney Disease on Hemodialysis
Nutritional Status in Patients With Chronic Kidney Disease Receiving 7.2% Amino Acids During Hemodialysis
Malnutrition and anemia are common among people with chronic kidney disease who receive maintenance hemodialysis. These conditions may worsen health outcomes and quality of life.
- Conditions
- Malnutitrion, Chronic Kidney Disease on Hemodialysis, Anemia (Diagnosis)
- Trial name
- NCT07881627
- Where
- Indonesia
- Volunteers
- 90 people
- Sponsor
- PT Otsuka Indonesia
Anemia
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in stage III-IV chronic kidney disease patients not on dialysis receiving Mircera for the…
- Trial name
- NCT01695746
- Testing
- C.E.R.A.
- Where
- 6 sites in India
- Volunteers
- 108 people
- Sponsor
- Hoffmann-La Roche
Sickle Cell Disease, Nephropathy
A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
The primary purpose of this study is to evaluate the effect of mitapivat on albumin creatinine ratio (ACR) response in participants with sickle cell disease (SCD) and nephropathy.
- Trial name
- NCT06286046
- Testing
- Mitapivat
- Sponsor
- Agios Pharmaceuticals, Inc.
Atypical Hemolytic Uremic Syndrome (aHUS)
The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Protocol is intended to characterize the overall safety and tolerability of eculizumab in this population.
- Trial name
- NCT01757431
- Testing
- Eculizumab
- Where
- 2 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Anemia, Kidney Disease
42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
The purpose of this study is to evaluate the dose response (efficacy), pharmacodynamic response, pharmacokinetics, safety, and tolerability of orally administered AKB-6548 in pre-dialysis participants with anemia with repeat…
- Trial name
- NCT01381094
- Testing
- AKB-6548
- Where
- 28 sites in United States
- Volunteers
- 93 people
- Sponsor
- Akebia Therapeutics
Anemia, Kidney Failure, Chronic
A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis
To determine the optimal route of administration, dose level, and safety of intravenous and subcutaneous dosing of sotatercept for maintaining hemoglobin levels in subjects who are on hemodialysis.
- Trial name
- NCT01999582
- Testing
- Sotatercept
- Where
- 23 sites in Belgium, Germany and 3 more
- Volunteers
- 50 people
- Sponsor
- Celgene
Anemia, Hemodialysis
ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis
To assess the Pharmacokinetics and pharmacodynamics of single doses of ASP1517 in renal anemia patients on hemodialysis. Safety and tolerability will be also evaluated in these patients.
- Conditions
- Anemia, Hemodialysis, Renal Impairment
- Trial name
- NCT01083888
- Testing
- roxadustat
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Inc
Anemia
Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis
The purpose of the study was to compare the efficacy of oral iron (ferrous sulfate) plus erythropoietin to Iron Sucrose plus erythropoietin for managing anemia patients with chronic renal failure who are not receiving dialysis.
- Trial name
- NCT00236964
- Testing
- Iron Sucrose + Erythropoietin, Oral Iron + Erythropoietin
- Volunteers
- 96 people
- Sponsor
- American Regent, Inc.
Kidney Disease, Diabetes Mellitus
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage…
- Conditions
- Kidney Disease, Diabetes Mellitus, Anemia
- Trial name
- NCT00093015
- Testing
- darbepoetin alfa
- Volunteers
- 4,038 people
- Sponsor
- Amgen
Kidney Disease, Chronic
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis
This observational, prospective, multicenter study will describe the mean dose of Mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels in patients with chronic kidney disease.
- Trial name
- NCT01318512
- Where
- Czechia
- Volunteers
- 340 people
- Sponsor
- Hoffmann-La Roche
Fanconi Anemia Complementation Group A
Gene Therapy for Fanconi Anemia, Complementation Group A
The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A).
- Trial name
- NCT04248439
- Testing
- RP-L102
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Anemia, Chronic Kidney Disease
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
The primary objectives of this study are the following: 1. To test if the proportion of participants achieving a hemoglobin value greater than or equal to 10.0 g/dL at any time point after the first dose during the study is…
- Conditions
- Anemia, Chronic Kidney Disease, Kidney Disease
- Trial name
- NCT00436748
- Testing
- Darbepoetin Alfa
- Where
- 67 sites in United States, Belgium and 8 more
- Volunteers
- 116 people
- Sponsor
- Amgen
Anemia
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.
- Trial name
- NCT02174731
- Testing
- Roxadustat, Epoetin alfa
- Where
- 188 sites in United States, Australia and 16 more
- Volunteers
- 2,133 people
- Sponsor
- AstraZeneca
Anemia in Chronic Kidney Disease
An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD
FMX-8 is a new type of drug being tested for the treatment of anemia in chronic illnesses.
- Trial name
- NCT02228655
- Testing
- FMX-8
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- FerruMax Pharmaceuticals, Inc.
Atypical Hemolytic Uremic Syndrome, aHUS
Observational Study of Elizaria® in aHUS Patients
It is a multicenter observational non-comparative study of the efficacy and safety of long-term pathogenetic Elizaria® therapy in patients with atypical Hemolytic Uremic Syndrome
- Trial name
- NCT04749810
- Testing
- Elizaria®
- Where
- 8 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AO GENERIUM
Chronic Kidney Disease, End Stage Renal Disease
TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.
- Trial name
- NCT02117427
- Testing
- MDGN201 TARGTEPO
- Where
- 5 sites in Israel
- Volunteers
- 11 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Anemia
An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)
This prospective, multicenter, observational study will evaluate the impact of comorbidities on hemoglobin stability in chronic kidney disease patients on dialysis treated with Mircera (methoxy polyethylene glycol-epoetin beta).
- Trial name
- NCT01974271
- Where
- 76 sites in France
- Volunteers
- 661 people
- Sponsor
- Hoffmann-La Roche
Anemia, End Stage Renal Disease
Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients
Dialysis patients regularly suffer from anemia which may be caused by various contributing factors, alone or in combination, including blood loss, low erythropoietin and iron sequestration.
- Trial name
- NCT02079896
- Testing
- Lexaptepid pegol (NOX-H94)
- Where
- 10 sites in Germany, Italy and 1 more
- Volunteers
- 33 people
- Sponsor
- TME Pharma AG
Anemia; Non-dialysis Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
For Non-dialysis subjects with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.
- Trial name
- NCT03329196
- Testing
- MT-6548, Darbepoetin alfa
- Where
- 31 sites in Japan
- Volunteers
- 304 people
- Sponsor
- Tanabe Pharma Corporation
Anemia, Renal Insufficiency, Chronic
Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
Evaluate efficacy and safety up to 36 months of titrated dose treatment with BAY85-3934 versus epoetin alfa/beta. Titration will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose.
- Trial name
- DIALOGUE5 (NCT02064426)
- Testing
- Molidustat (BAY85-3934), Epoetin alfa/beta
- Where
- 26 sites in United States, Japan
- Volunteers
- 88 people
- Sponsor
- Bayer